
Signalisation PI3K/Akt/mTOR
Les inhibiteurs de la signalisation PI3K/Akt/mTOR sont des composés qui ciblent les voies de la phosphoinositide 3-kinase (PI3K), de la kinase Akt et de la cible de la rapamycine chez les mammifères (mTOR). Ces voies sont des régulateurs critiques de la croissance cellulaire, de la survie, du métabolisme et de l'autophagie, ce qui en fait des cibles clés dans la recherche sur le cancer et les troubles métaboliques. Inhiber ces voies peut aider à contrôler la croissance et la prolifération tumorales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies caractérisées par une signalisation cellulaire dysrégulée. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de haute qualité de PI3K/Akt/mTOR pour soutenir vos recherches en oncologie, signalisation cellulaire et maladies métaboliques.
Sous-catégories appartenant à la catégorie "Signalisation PI3K/Akt/mTOR"
- AMPK(159 produits)
- ATM/ATR(71 produits)
- ADN-PK(50 produits)
- EGFR(572 produits)
- MELK(7 produits)
- PDK(9 produits)
- PI3K(241 produits)
- S6 Kinase(9 produits)
- gsk-3(111 produits)
- mTOR(144 produits)
Affichez 2 plus de sous-catégories
1030 produits trouvés pour "Signalisation PI3K/Akt/mTOR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
PI3Kδ-IN-23
CAS :<p>PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with an IC50 of 0.27 nM. It binds to PI3Kδ through covalent interaction with Lys779 and plays a significant role in cancer research.</p>Formule :C30H30N6O5Couleur et forme :SolidMasse moléculaire :554.596PI3K-IN-23
<p>PI3K-IN-23 is a (E)-9-oxooctadec-10-en-12-ynoic acid analogue that promotes glucose uptake (EC50: 7.00 μM).</p>Formule :C24H33NO4SCouleur et forme :SolidMasse moléculaire :431.595-Bromo-3-indoxylacetate
CAS :<p>5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.</p>Formule :C10H8BrNO2Couleur et forme :SolidMasse moléculaire :254.08EG31
CAS :<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98PI3K-IN-26
CAS :<p>PI3K-IN-26 is an effective PI3K inhibitor. PI3K-IN-26 inhibits the proliferation of SU-DHL-6 cells, IC50= 36 nM.</p>Formule :C21H18N6OSCouleur et forme :SolidMasse moléculaire :402.47EGFR-IN-160
CAS :EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27GSK3β-IN-2
CAS :<p>GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.</p>Formule :C25H18N4OCouleur et forme :SolidMasse moléculaire :390.437Tarloxotinib bromide
CAS :Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formule :C24H24Br2ClN9O3Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :681.77PIKfyve-IN-1
<p>PIKfyve-IN-1: potent, cell-active inhibitor for PIKfyve research, IC50=6.9 nM.</p>Formule :C20H21N5Couleur et forme :SolidMasse moléculaire :331.41Aldometanib
CAS :<p>Aldometanib (LXY-05-029) is an oral aldolase inhibitor that maintains metabolic balance by blocking FBP and activating lysosomal AMPK.</p>Formule :C27H43Cl2IN2Degré de pureté :99.32% - 99.55%Couleur et forme :SolidMasse moléculaire :593.46AZD 3147
CAS :<p>AZD 3147 inhibits mTORC1 (40.7 nM), mTORC2 (5.75 nM), and PI3Kα/β/δ/γ (912/5495/9333/6310 nM IC50s).</p>Formule :C24H31N5O4S2Degré de pureté :99.99%Couleur et forme :SolidMasse moléculaire :517.66BAY-8400
<p>BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase ( DNA-PK ) inhibitor ( IC 50 =81 nM) which shows synergistic efficacy in</p>Formule :C21H17F2N5ODegré de pureté :99.53%Couleur et forme :SolidMasse moléculaire :393.39EGFR-IN-7
CAS :<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formule :C32H41BrN9O2PDegré de pureté :95.32% - 99.64%Couleur et forme :SolidMasse moléculaire :694.6Sonolisib
CAS :<p>Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)).</p>Formule :C29H35NO8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :525.59HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Couleur et forme :Odour LiquidNimotuzumab (powder)
CAS :<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Couleur et forme :LiquidTLC9995-0188
CAS :<p>Tyrosine-protein kinase ABL, IC50: 1500 nM</p>Formule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331AS-604850
<p>AS-604850: PI3Kγ inhibitor, ATP-competitive, IC50=2.5μM, 30x> PI3Kδ/β, 18x> PI3Kα.</p>Formule :C11H5F2NO4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :285.22AZD8154
CAS :<p>AZD8154 is a newly developed inhaled compound that selectively inhibits dual PI3Kγδ, aimed at treating airway inflammatory diseases.</p>Formule :C27H29N5O4S2Couleur et forme :SolidMasse moléculaire :551.68mTORC1-IN-1
<p>mTORC1-IN-1 (T1), a rapamycin homologue (rapalog) and selective inhibitor of mTORC1, controls cell growth and metabolism, with implications in various diseases</p>Degré de pureté :98%Couleur et forme :Odour SolidDuligotuzumab
CAS :<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Degré de pureté :95%Couleur et forme :LiquidEGFR-IN-82
CAS :<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formule :C32H41BrN9O2PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :694.6Bisindolylmaleimide I HCl
CAS :<p>Bisindolylmaleimide I HCl is a specific ATP-competitive PKC inhibitor.</p>Formule :C25H25ClN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.95PI3Kδ-IN-13
CAS :<p>PI3Kδ-IN-13 (compound 89), with an IC50 value of 2.6 nM, is an inhibitor of PI3Kδ, applicable for researching diseases involving cell proliferation, including</p>Formule :C27H39N7O4S2Couleur et forme :SolidMasse moléculaire :589.77MDVN1003
CAS :<p>MDVN1003 inhibits BTK & PI3Kδ in B cells, blocking NHL growth; it kills lymphoma cells, not erythroblasts.</p>Formule :C22H20FN7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :417.44YK-029A
CAS :<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formule :C27H32N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :500.6Duvelisib (R enantiomer)
CAS :Duvelisib R enantiomer (IPI-145 R enantiomer) is an enantiomer of Duvelisib with lower activity. Duvelisib is a PI3K inhibitor.Formule :C22H17ClN6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :416.86EGFR-IN-122
CAS :<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formule :C19H20N4O3Couleur et forme :SolidMasse moléculaire :352.39EGFR-IN-123
CAS :<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formule :C24H27F3N6OCouleur et forme :SolidMasse moléculaire :472.51

